1 out of 4 people will sustain at least 1 traumatic brain injury during their lifetime.
TBI is the leading cause of death and disability in people under 45 years of age, occurring more frequently than breast cancer, ovarian cancer, AIDS, and multiple sclerosis combined.
Currently, there are zero FDA approved drugs to mitigate the long-term effects of traumatic brain injuries.
TheBIRF has developed the Traumatic Brain Injury Treatment Accelerator Program (TBITXL) which brings together the worlds brightest neuroscientists to solve the world’s toughest problem.
At its core, TBITXL aims to address critical unmet needs in TBI drug development by
incorporating the voice of patients, biotech companies, academia, & regulatory agencies. Its primary goal is to overcome the challenges often encountered in collaborative efforts between these entities.
To decrease the cost and improve the rate and effectiveness of successful traumatic brain injury drug launches.
TheBIRF and its partners are laser-focused on enhancing our comprehension of
neurodegenerative pathways that hold therapeutic potential. If you would like to work with us to develop the first medication to treat traumatic brain injuries, contact our team below.